Research Focus

Former Employee. Pediatrics; Clinical Research Supervisor

Recent additions – View all

1. Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents

   Meeting Abstract

   Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
   Blood (2018)

   Fulltext@MSK | Save
2. Phase 2 study of selinexor in patients with myelodysplastic syndromes refractory to hypomethylating agents: Interim report

   Meeting Abstract

   Klimek, V. M.; Coleman, M.; Alvarez, K.; Sen, F.; Pichardo, J.; Kashyap, T.; Klebanov, B.
   Leukemia Research (2017)

   Fulltext@MSK | Save